{
    "data": [
        {
            "id": "4394350",
            "type": "article",
            "attributes": {
                "publishOn": "2020-12-11T16:21:41-05:00",
                "isLockedPro": false,
                "commentCount": 53,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie: No Sense Of (Post) Humira Failure - My Price Target Is $120 - $150",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104985",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "304536",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4394350-abbvie-no-sense-of-post-humira-failure-price-target-is-120-150"
            }
        },
        {
            "id": "4390204",
            "type": "article",
            "attributes": {
                "publishOn": "2020-11-19T08:30:08-05:00",
                "isLockedPro": false,
                "commentCount": 80,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "5%-Yielding AbbVie: Double-Digit Dividend Raise And A Buffett Endorsement",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "68315",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "301489",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4390204-5-percent-yielding-abbvie-double-digit-dividend-raise-and-buffett-endorsement"
            }
        },
        {
            "id": "4390203",
            "type": "article",
            "attributes": {
                "publishOn": "2020-11-19T01:44:33-05:00",
                "isLockedPro": false,
                "commentCount": 22,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie Should Benefit From A Buffett Bounce",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24443",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "301239",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4390203-abbvie-should-benefit-from-buffett-bounce"
            }
        },
        {
            "id": "4387478",
            "type": "article",
            "attributes": {
                "publishOn": "2020-11-10T06:29:16-05:00",
                "isLockedPro": false,
                "commentCount": 44,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "GlaxoSmithKline Or AbbVie: Choices In High-Yield Pharma",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105192",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "299217",
                            "type": "sentiment"
                        },
                        {
                            "id": "299218",
                            "type": "sentiment"
                        },
                        {
                            "id": "299219",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/4387478-glaxosmithkline-abbvie-choices-in-high-yield-pharma"
            }
        },
        {
            "id": "4387271",
            "type": "article",
            "attributes": {
                "publishOn": "2020-11-09T17:36:24-05:00",
                "isLockedPro": false,
                "commentCount": 118,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie: Delivering Yet Another Double-Digit Dividend Increase",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104980",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "297946",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4387271-abbvie-delivering-yet-another-double-digit-dividend-increase"
            }
        },
        {
            "id": "4381268",
            "type": "article",
            "attributes": {
                "publishOn": "2020-10-26T09:30:25-04:00",
                "isLockedPro": false,
                "commentCount": 117,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Inexpensive AbbVie's High Dividend Yield Makes It A Buy",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "68315",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "298026",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4381268-inexpensive-abbvies-high-dividend-yield-makes-buy"
            }
        },
        {
            "id": "4381114",
            "type": "article",
            "attributes": {
                "publishOn": "2020-10-24T07:00:00-04:00",
                "isLockedPro": false,
                "commentCount": 202,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "5.7% Yielding AbbVie Represents One Of The Fattest Pitches On Wall Street Today",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24223",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "297818",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4381114-5_7-percent-yielding-abbvie-represents-one-of-fattest-pitches-on-wall-street-today"
            }
        },
        {
            "id": "4380120",
            "type": "article",
            "attributes": {
                "publishOn": "2020-10-20T19:41:35-04:00",
                "isLockedPro": false,
                "commentCount": 97,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie: Stock Will Break $100 Once Management And Market Are On Same Page",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104985",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "297284",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4380120-abbvie-stock-will-break-100-management-and-market-are-on-page"
            }
        },
        {
            "id": "4379889",
            "type": "article",
            "attributes": {
                "publishOn": "2020-10-20T02:06:21-04:00",
                "isLockedPro": false,
                "commentCount": 96,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie: Now It's Time To Dollar-Cost-Average On This 5.6% Yield",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105703",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "297232",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4379889-abbvie-now-time-to-dollar-cost-average-on-this-5_6-percent-yield"
            }
        },
        {
            "id": "4379160",
            "type": "article",
            "attributes": {
                "publishOn": "2020-10-15T04:16:20-04:00",
                "isLockedPro": false,
                "commentCount": 186,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Buy AbbVie Before It Raises Dividends Again",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "22786",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "296512",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4379160-buy-abbvie-raises-dividends-again"
            }
        },
        {
            "id": "4375609",
            "type": "article",
            "attributes": {
                "publishOn": "2020-09-22T08:30:10-04:00",
                "isLockedPro": false,
                "commentCount": 111,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie: I Don't Wanna Miss This Thing",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101935",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "293269",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4375609-abbvie-i-dont-wanna-miss-this-thing"
            }
        },
        {
            "id": "4375084",
            "type": "article",
            "attributes": {
                "publishOn": "2020-09-18T05:35:28-04:00",
                "isLockedPro": false,
                "commentCount": 46,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie - Still A 20% Undervalued, High-Yielding Buy",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105093",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "292454",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/4375084-abbvie-still-20-percent-undervalued-high-yielding-buy"
            }
        },
        {
            "id": "4374990",
            "type": "article",
            "attributes": {
                "publishOn": "2020-09-17T16:04:49-04:00",
                "isLockedPro": false,
                "commentCount": 116,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie: High Yield Dividend Anxiety",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101378",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "292060",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4374990-abbvie-high-yield-dividend-anxiety"
            }
        },
        {
            "id": "4374883",
            "type": "article",
            "attributes": {
                "publishOn": "2020-09-17T09:17:14-04:00",
                "isLockedPro": false,
                "commentCount": 34,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie: The Best Dividend Growth Challenger In The Margin Of Safety",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105646",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "292745",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4374883-abbvie-best-dividend-growth-challenger-in-margin-of-safety"
            }
        },
        {
            "id": "4374345",
            "type": "article",
            "attributes": {
                "publishOn": "2020-09-15T07:34:24-04:00",
                "isLockedPro": false,
                "commentCount": 49,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie: The Time Is Now",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "39011",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "292444",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4374345-abbvie-time-is-now"
            }
        },
        {
            "id": "4372548",
            "type": "article",
            "attributes": {
                "publishOn": "2020-09-04T00:54:37-04:00",
                "isLockedPro": false,
                "commentCount": 28,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Humira Battles: AbbVie's Upa Versus Gilead's Filgo-Redux",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101378",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "289929",
                            "type": "sentiment"
                        },
                        {
                            "id": "289930",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4372548-humira-battles-abbvies-upa-versus-gileads-filgo-redux"
            }
        },
        {
            "id": "4371659",
            "type": "article",
            "attributes": {
                "publishOn": "2020-08-31T10:00:00-04:00",
                "isLockedPro": false,
                "commentCount": 63,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie: Dividend Growth Stock Trading At A BIG Discount",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103599",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "290341",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4371659-abbvie-dividend-growth-stock-trading-big-discount"
            }
        },
        {
            "id": "4371505",
            "type": "article",
            "attributes": {
                "publishOn": "2020-08-29T07:58:36-04:00",
                "isLockedPro": false,
                "commentCount": 79,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Why I Bought AbbVie Despite 43% Appreciation This Year",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "50452",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "290333",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4371505-why-i-bought-abbvie-despite-43-percent-appreciation-this-year"
            }
        },
        {
            "id": "4370247",
            "type": "article",
            "attributes": {
                "publishOn": "2020-08-22T07:24:19-04:00",
                "isLockedPro": false,
                "commentCount": 104,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Market Neutral Strategy: Long AbbVie, Short Gilead",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "56142",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "289255",
                            "type": "sentiment"
                        },
                        {
                            "id": "289256",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4370247-market-neutral-strategy-long-abbvie-short-gilead"
            }
        },
        {
            "id": "4369444",
            "type": "article",
            "attributes": {
                "publishOn": "2020-08-18T09:37:12-04:00",
                "isLockedPro": false,
                "commentCount": 31,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie: A Solid 5% Yield With The Potential For Growth",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105636",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "288578",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4369444-abbvie-solid-5-percent-yield-potential-for-growth"
            }
        },
        {
            "id": "4369357",
            "type": "article",
            "attributes": {
                "publishOn": "2020-08-17T21:02:12-04:00",
                "isLockedPro": false,
                "commentCount": 46,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie: A Trifecta Of Yield, Growth, And Total Return Potential",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104980",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "287422",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4369357-abbvie-trifecta-of-yield-growth-and-total-return-potential"
            }
        },
        {
            "id": "4369185",
            "type": "article",
            "attributes": {
                "publishOn": "2020-08-17T11:34:12-04:00",
                "isLockedPro": false,
                "commentCount": 74,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "3 Reasons AbbVie Is Ready To Bounce",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "22786",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "288558",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4369185-3-reasons-abbvie-is-ready-to-bounce"
            }
        },
        {
            "id": "4367582",
            "type": "article",
            "attributes": {
                "publishOn": "2020-08-11T13:36:42-04:00",
                "isLockedPro": false,
                "commentCount": 84,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie: Another Opportunity",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "22148",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "287807",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4367582-abbvie-another-opportunity"
            }
        },
        {
            "id": "4359952",
            "type": "article",
            "attributes": {
                "publishOn": "2020-07-22T15:05:51-04:00",
                "isLockedPro": false,
                "commentCount": 110,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "3 Reasons You Should Buy AbbVie",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "22786",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "285054",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4359952-3-reasons-you-should-buy-abbvie"
            }
        },
        {
            "id": "4358371",
            "type": "article",
            "attributes": {
                "publishOn": "2020-07-14T10:25:32-04:00",
                "isLockedPro": false,
                "commentCount": 42,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie: Buy For The Blockbuster Sales And Dividend, Hold For The Future Promise",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104985",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "283615",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4358371-abbvie-buy-for-blockbuster-sales-and-dividend-hold-for-future-promise"
            }
        },
        {
            "id": "4357846",
            "type": "article",
            "attributes": {
                "publishOn": "2020-07-10T13:43:59-04:00",
                "isLockedPro": false,
                "commentCount": 100,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie Is About To Break Out",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24443",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "283285",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4357846-abbvie-is-to-break-out"
            }
        },
        {
            "id": "4357820",
            "type": "article",
            "attributes": {
                "publishOn": "2020-07-10T11:06:00-04:00",
                "isLockedPro": false,
                "commentCount": 44,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie: The Most Undervalued Income Stock",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105567",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "283263",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4357820-abbvie-undervalued-income-stock"
            }
        },
        {
            "id": "4356898",
            "type": "article",
            "attributes": {
                "publishOn": "2020-07-03T10:31:42-04:00",
                "isLockedPro": false,
                "commentCount": 289,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "3 Reasons AbbVie Could Make You Rich",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "68315",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "282507",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4356898-3-reasons-abbvie-make-you-rich"
            }
        },
        {
            "id": "4356754",
            "type": "article",
            "attributes": {
                "publishOn": "2020-07-02T12:14:13-04:00",
                "isLockedPro": false,
                "commentCount": 93,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie: The End Of Suffering",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101935",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "282314",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4356754-abbvie-end-of-suffering"
            }
        },
        {
            "id": "4356021",
            "type": "article",
            "attributes": {
                "publishOn": "2020-06-28T12:10:31-04:00",
                "isLockedPro": false,
                "commentCount": 100,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie: This Blue Chip Name Offers Strong Double Digit Total Returns",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "44781",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "281765",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4356021-abbvie-this-blue-chip-name-offers-strong-double-digit-total-returns"
            }
        },
        {
            "id": "4355818",
            "type": "article",
            "attributes": {
                "publishOn": "2020-06-26T08:08:57-04:00",
                "isLockedPro": false,
                "commentCount": 44,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie: Stock Remains Extremely Attractive Despite Recent Price Appreciation",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "71565",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "281545",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4355818-abbvie-stock-remains-extremely-attractive-despite-recent-price-appreciation"
            }
        },
        {
            "id": "4354126",
            "type": "article",
            "attributes": {
                "publishOn": "2020-06-16T13:38:59-04:00",
                "isLockedPro": false,
                "commentCount": 50,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie: A High-Quality Stock Positioned For Strong Growth",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103599",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "279949",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4354126-abbvie-high-quality-stock-positioned-for-strong-growth"
            }
        },
        {
            "id": "4354002",
            "type": "article",
            "attributes": {
                "publishOn": "2020-06-15T22:07:32-04:00",
                "isLockedPro": false,
                "commentCount": 82,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Income Strategy: High Yield With Deep Downside Protection, An AbbVie Example",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "42661",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "279974",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4354002-income-strategy-high-yield-deep-downside-protection-abbvie-example"
            }
        },
        {
            "id": "4350183",
            "type": "article",
            "attributes": {
                "publishOn": "2020-05-27T01:55:58-04:00",
                "isLockedPro": false,
                "commentCount": 281,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Don't Gamble In The Markets, Look At These 2 Blue Chip Healthcare Names Instead",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "44781",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "277254",
                            "type": "sentiment"
                        },
                        {
                            "id": "277255",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4350183-dont-gamble-in-markets-look-2-blue-chip-healthcare-names-instead"
            }
        },
        {
            "id": "4348564",
            "type": "article",
            "attributes": {
                "publishOn": "2020-05-18T17:00:18-04:00",
                "isLockedPro": false,
                "commentCount": 30,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie: A Post Allergan Powerhouse",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "80516",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "276025",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4348564-abbvie-post-allergan-powerhouse"
            }
        },
        {
            "id": "4347901",
            "type": "article",
            "attributes": {
                "publishOn": "2020-05-15T08:00:58-04:00",
                "isLockedPro": false,
                "commentCount": 23,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie And The Successful LBO Of Allergan",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "56142",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "275529",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4347901-abbvie-and-successful-lbo-of-allergan"
            }
        },
        {
            "id": "4347720",
            "type": "article",
            "attributes": {
                "publishOn": "2020-05-14T17:10:10-04:00",
                "isLockedPro": false,
                "commentCount": 46,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie Plus Allergan: Reasonable Valuation And Dynamic Dividend Growth",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "59101",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "275379",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4347720-abbvie-plus-allergan-reasonable-valuation-and-dynamic-dividend-growth"
            }
        },
        {
            "id": "4346173",
            "type": "article",
            "attributes": {
                "publishOn": "2020-05-11T14:33:58-04:00",
                "isLockedPro": false,
                "commentCount": 8,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Merger Arb Trade Review: AbbVie And Allergan",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105284",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "274723",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4346173-merger-arb-trade-review-abbvie-and-allergan"
            }
        },
        {
            "id": "4344785",
            "type": "article",
            "attributes": {
                "publishOn": "2020-05-08T12:23:09-04:00",
                "isLockedPro": false,
                "commentCount": 57,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie: Redeploy The Allergan Cash",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "22148",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "274256",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4344785-abbvie-redeploy-allergan-cash"
            }
        },
        {
            "id": "4343810",
            "type": "article",
            "attributes": {
                "publishOn": "2020-05-06T17:14:22-04:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Breaking Bio: Drug Makers Cooking Off March Lows (Video)",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "53262",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "274115",
                            "type": "sentiment"
                        },
                        {
                            "id": "274116",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4343810-breaking-bio-drug-makers-cooking-off-march-lows-video"
            }
        },
        {
            "id": "4339494",
            "type": "article",
            "attributes": {
                "publishOn": "2020-04-23T13:42:24-04:00",
                "isLockedPro": false,
                "commentCount": 40,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie: Strong Growth Ahead",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103599",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "271734",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4339494-abbvie-strong-growth-ahead"
            }
        },
        {
            "id": "4339415",
            "type": "article",
            "attributes": {
                "publishOn": "2020-04-23T10:28:06-04:00",
                "isLockedPro": false,
                "commentCount": 3,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie's Label Expansion, And Other News: The Good, Bad And Ugly Of Biopharma",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103050",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "271936",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4339415-abbvies-label-expansion-and-news-good-bad-and-ugly-of-biopharma"
            }
        },
        {
            "id": "4338677",
            "type": "article",
            "attributes": {
                "publishOn": "2020-04-20T23:38:44-04:00",
                "isLockedPro": false,
                "commentCount": 25,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie: A Strong Dividend Growth Pharmaceutical Company That Carries Risk",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105636",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "271144",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4338677-abbvie-strong-dividend-growth-pharmaceutical-company-carries-risk"
            }
        },
        {
            "id": "4338023",
            "type": "article",
            "attributes": {
                "publishOn": "2020-04-16T13:39:38-04:00",
                "isLockedPro": false,
                "commentCount": 21,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie Inc.: The Opportunity, The Risks",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "41431",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "270558",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4338023-abbvie-inc-opportunity-risks"
            }
        },
        {
            "id": "4338001",
            "type": "article",
            "attributes": {
                "publishOn": "2020-04-16T12:45:13-04:00",
                "isLockedPro": false,
                "commentCount": 13,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie: Powerful R&D Portfolio Backing Strong Shareholder Returns",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "80516",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "270698",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4338001-abbvie-powerful-r-and-d-portfolio-backing-strong-shareholder-returns"
            }
        },
        {
            "id": "4335443",
            "type": "article",
            "attributes": {
                "publishOn": "2020-04-01T09:53:03-04:00",
                "isLockedPro": false,
                "commentCount": 187,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie: Illogical 6.3% Yield",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "22148",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "268139",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4335443-abbvie-illogical-6_3-percent-yield"
            }
        },
        {
            "id": "4334174",
            "type": "article",
            "attributes": {
                "publishOn": "2020-03-25T14:32:44-04:00",
                "isLockedPro": false,
                "commentCount": 26,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie: Set To Retrace To Previous Highs",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104820",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "267139",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4334174-abbvie-set-to-retrace-to-previous-highs"
            }
        },
        {
            "id": "4333699",
            "type": "article",
            "attributes": {
                "publishOn": "2020-03-23T14:07:10-04:00",
                "isLockedPro": false,
                "commentCount": 55,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbvie: Buy The Coronavirus Dip For These 3 Reasons",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103599",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "266621",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4333699-abbvie-buy-coronavirus-dip-for-3-reasons"
            }
        },
        {
            "id": "4333154",
            "type": "article",
            "attributes": {
                "publishOn": "2020-03-19T19:40:01-04:00",
                "isLockedPro": false,
                "commentCount": 28,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie Is Your Egg In The Basket Now",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105218",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "265218",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4333154-abbvie-is-your-egg-in-basket-now"
            }
        },
        {
            "id": "4324983",
            "type": "article",
            "attributes": {
                "publishOn": "2020-02-18T14:27:27-05:00",
                "isLockedPro": false,
                "commentCount": 61,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie's Annual Total Return Is Likely To Double The Market Over The Next Decade",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104980",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "260588",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4324983-abbvies-annual-total-return-is-likely-to-double-market-over-next-decade"
            }
        },
        {
            "id": "4323867",
            "type": "article",
            "attributes": {
                "publishOn": "2020-02-13T11:21:59-05:00",
                "isLockedPro": false,
                "commentCount": 33,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Allergan + Cash Becomes More Compelling - February 12 Update",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "41431",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "261210",
                            "type": "sentiment"
                        },
                        {
                            "id": "261211",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4323867-allergan-cash-becomes-compelling-february-12-update"
            }
        },
        {
            "id": "4323184",
            "type": "article",
            "attributes": {
                "publishOn": "2020-02-11T14:09:13-05:00",
                "isLockedPro": false,
                "commentCount": 129,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie: $100 Next",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "22786",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "260969",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4323184-abbvie-100-next"
            }
        },
        {
            "id": "4319239",
            "type": "article",
            "attributes": {
                "publishOn": "2020-01-27T10:48:44-05:00",
                "isLockedPro": false,
                "commentCount": 57,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie: Potential 20% To 30% Share Price Gains",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "41431",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "254985",
                            "type": "sentiment"
                        },
                        {
                            "id": "254986",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4319239-abbvie-potential-20-percent-to-30-percent-share-price-gains"
            }
        },
        {
            "id": "4317971",
            "type": "article",
            "attributes": {
                "publishOn": "2020-01-21T08:45:06-05:00",
                "isLockedPro": false,
                "commentCount": 88,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie: Undervalued And Poised For A 2020 Breakout",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101935",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "256182",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4317971-abbvie-undervalued-and-poised-for-2020-breakout"
            }
        },
        {
            "id": "4317901",
            "type": "article",
            "attributes": {
                "publishOn": "2020-01-20T12:02:33-05:00",
                "isLockedPro": false,
                "commentCount": 80,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie Stock's 7.3% Total Yield Leaves It Very Undervalued",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "22717",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "256045",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4317901-abbvie-stocks-7_3-percent-total-yield-leaves-undervalued"
            }
        },
        {
            "id": "4317282",
            "type": "article",
            "attributes": {
                "publishOn": "2020-01-16T11:02:53-05:00",
                "isLockedPro": false,
                "commentCount": 60,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Like AbbVie, Buy Allergan, It's A No-Brainer",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "41431",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "253136",
                            "type": "sentiment"
                        },
                        {
                            "id": "253137",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4317282-like-abbvie-buy-allergan-no-brainer"
            }
        },
        {
            "id": "4316881",
            "type": "article",
            "attributes": {
                "publishOn": "2020-01-14T17:07:58-05:00",
                "isLockedPro": false,
                "commentCount": 14,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie And Allergan Merger, And Other News: The Good, Bad And Ugly Of Biopharma",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103050",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "254758",
                            "type": "sentiment"
                        },
                        {
                            "id": "254828",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4316881-abbvie-and-allergan-merger-and-news-good-bad-and-ugly-of-biopharma"
            }
        }
    ]
}